Skip to main content

Table 6 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]

From: Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

  p HR 95% CI
B. Multivariate analysis
ER+/HER2- (n=332)
Age (<50 vs. ≥50 years) 0.920 1.025 0.634-1.656
pT stage (≤2cm vs. >2cm) 0.004 2.143 1.271-3.613
Histological grade (Grade 1 and 2 vs. grade 3) 0.456 1.255 0.691-2.283
AURKA (continuous variable) 0.001 1.734 1.242-2.419
  p HR 95 % CI
ER-/HER2- (n=80)
Age (<50 vs. ≥50 years) 0.644 0.825 0.365-1.865
pT stage (≤2cm vs. >2cm) 0.466 1.459 0.528-4.028
Histological grade (Grade 1 and 2 vs. grade 3) 0.590 0.768 0.294-2.005
AURKA (continuous variable) 0.858 0.943 0.497-1.791
  p HR 95 % CI
HER2+ (n=53)
Age (<50 vs. ≥50 years) 0.018 5.072 1.327-19.383
pT stage (≤2cm vs. >2cm) 0.485 1.510 0.475-4.802
Histological grade (Grade 1 and 2 vs. grade 3) 0.001 15.527 3.223-74.793
AURKA (continuous variable) 0.001 0.146 0.045-0.466
  1. AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. B. Multivariate Cox regression.